TY - JOUR
T1 - Utility of the montreal cognitive assessment as a screening test for neurocognitive dysfunction in adults with sickle cell disease
AU - Cichowitz, Cody
AU - Carroll, Patrick C.
AU - Strouse, John J.
AU - Haywood, Carlton
AU - Lanzkron, Sophie
N1 - Funding Information:
J.J.S. has institutional grants from the Health Resources and Services Administration and theMaryland Department ofMentalHealth andHygiene, grants from the National Institutes of Health-National Heart, Lung, and Blood Institute, and honoraria from the Johns Hopkins University, the University of Alabama, Birmingham, and the National Institutes of Health. S. L. has received grant support (#K23HL083089) from the National Heart, Lung, and Blood Institute and institutional support from the Patient-Centered Outcomes Research Institute, Selexys, and Pfizer. C.H. has received grant support (#K01HL108832-01) from the National Heart, Lung, and Blood Institute.
Publisher Copyright:
© 2016 by The Southern Medical Association.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Objectives Neurocognitive dysfunction is an important complication of sickle cell disease (SCD), but little is published on the utility of screening tests for cognitive impairment in people with the disease. The purpose of this study was to evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool and identify predictors of MoCA performance in adults with sickle cell disease. Methods We conducted a retrospective, cross-sectional study of the first 100 adult patients with SCD who completed the MoCA as part of routine clinical care at the Johns Hopkins Sickle Cell Center for Adults. We abstracted demographic, laboratory, and clinical data from each participant's electronic medical record up to the date that the MoCA was administered. The factorial validity of each MoCA domain was analyzed using standard psychometric statistics. We evaluated the abstracted data for associations with the composite MoCA score and looked for independent predictors of performance using multivariable regressions. Results Components of the MoCA performed well in psychometric analyses and identified deficits in executive function that were described in other studies. Forty-six percent of participants fell below the cutoff for mild cognitive impairment. Increased education was an independent predictor of increased MoCA score (3.1, 95% confidence interval [CI] 1.5-4.7), whereas cerebrovascular accidents and chronic kidney disease were independent predictors of decreased score (-3.3, 95% CI -5.7 to -0.97 and -3.2, 95% CI -6.2 to -0.11, respectively). When analysis was restricted to patients with SCA, increased education (3.7, 95% CI 2.2-5.2) and a history of hydroxyurea therapy (2.0, 95% CI -0.022 to 4.0) were independent predictors of a higher score, whereas chronic kidney disease (-3.3, 95% CI -6.4 to -0.24) and increased aspartate transaminase (-0.045, 95% CI -0.089 to -0.0010) were independent predictors of a decreased score. Conclusions The MoCA showed promise by identifying important cognitive deficits and associations with chronic complications and therapy.
AB - Objectives Neurocognitive dysfunction is an important complication of sickle cell disease (SCD), but little is published on the utility of screening tests for cognitive impairment in people with the disease. The purpose of this study was to evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool and identify predictors of MoCA performance in adults with sickle cell disease. Methods We conducted a retrospective, cross-sectional study of the first 100 adult patients with SCD who completed the MoCA as part of routine clinical care at the Johns Hopkins Sickle Cell Center for Adults. We abstracted demographic, laboratory, and clinical data from each participant's electronic medical record up to the date that the MoCA was administered. The factorial validity of each MoCA domain was analyzed using standard psychometric statistics. We evaluated the abstracted data for associations with the composite MoCA score and looked for independent predictors of performance using multivariable regressions. Results Components of the MoCA performed well in psychometric analyses and identified deficits in executive function that were described in other studies. Forty-six percent of participants fell below the cutoff for mild cognitive impairment. Increased education was an independent predictor of increased MoCA score (3.1, 95% confidence interval [CI] 1.5-4.7), whereas cerebrovascular accidents and chronic kidney disease were independent predictors of decreased score (-3.3, 95% CI -5.7 to -0.97 and -3.2, 95% CI -6.2 to -0.11, respectively). When analysis was restricted to patients with SCA, increased education (3.7, 95% CI 2.2-5.2) and a history of hydroxyurea therapy (2.0, 95% CI -0.022 to 4.0) were independent predictors of a higher score, whereas chronic kidney disease (-3.3, 95% CI -6.4 to -0.24) and increased aspartate transaminase (-0.045, 95% CI -0.089 to -0.0010) were independent predictors of a decreased score. Conclusions The MoCA showed promise by identifying important cognitive deficits and associations with chronic complications and therapy.
KW - Key Words cognitive impairment
KW - Montreal Cognitive Assessment
KW - screening
KW - sickle cell disease
UR - http://www.scopus.com/inward/record.url?scp=84985945788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84985945788&partnerID=8YFLogxK
U2 - 10.14423/SMJ.0000000000000511
DO - 10.14423/SMJ.0000000000000511
M3 - Article
C2 - 27598362
AN - SCOPUS:84985945788
SN - 0038-4348
VL - 109
SP - 560
EP - 565
JO - Southern Medical Journal
JF - Southern Medical Journal
IS - 9
ER -